Clinical Trial Update: A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma [Phase 1]

View source ↗

Summary

Phase 1 safety study of CP-675,206 administered as a one-hour infusion in patients with surgically incurable advanced melanoma; the trial was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CP-675,206

Snippet

Sponsor: AstraZeneca | Conditions: Melanoma | Phase 1 | Status: TERMINATED